|
Nov 13
|
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
|
|
Nov 2
|
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
|
|
Sep 4
|
Centessa (CNTA) Surges 72% in the Past 3 Months: Here's Why
|
|
Jul 10
|
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
|
|
Apr 27
|
Centessa Pharmaceuticals plc (NASDAQ:CNTA) most popular amongst private equity firms who own 42% of the shares, institutions hold 22%
|